Researchers have developed a new blood test that can detect ovarian cancer in its earliest stages with over 90 percent accuracy, significantly better than current diagnostic tools. Created by US-based AOA Dx, the test identifies unique lipid and protein fragments shed by cancer cells into the bloodstream, serving as a biological fingerprint.